---
title: "Merck Climbs 3% to Record After FDA Approves Oral Cholesterol Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293046381.md"
description: "Merck hits record high as FDA approves Lipfendra, first oral PCSK9 inhibitor for cholesterol treatment"
datetime: "2026-07-17T13:50:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293046381.md)
  - [en](https://longbridge.com/en/news/293046381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293046381.md)
---

# Merck Climbs 3% to Record After FDA Approves Oral Cholesterol Drug

默克 (MRK.US) 盘中涨近**3%**，现报**131.40**美元。

股价创下历史新高，主要受 FDA 批准消息推动。7 月 16 日，FDA 批准默克研发的口服降胆固醇药物 Lipfendra 上市，这是全球首款口服 PCSK9 抑制剂。该药物每日服用一次，可将低密度脂蛋白胆固醇降低 56%-59%，疗效与注射制剂相当，预计月费用为 315 美元。

此外，默克作为"十亿细胞图谱"项目的创始成员之一，该项目已完成超过 3.5 亿个细胞测序，有望助力新药靶点发现和药物机制研究。

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Aspen Pharmacare signs voluntary licensing deal with MSD for once-monthly HIV prevention pill MK-8527](https://longbridge.com/en/news/293755123.md)
- [Public Employees Retirement System of Ohio Has $125.54 Million Stock Position in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/293742074.md)
- [Merck (MRK) Wins FDA Approval For First Once Daily Oral PCSK9 Drug](https://longbridge.com/en/news/293099041.md)
- [FDA approves MSD’s Keytruda combinations for MIBC](https://longbridge.com/en/news/292462196.md)
- [Is Merck (MRK) Undervalued As KEYTRUDA Wins New FDA Approvals And Phase 3 Success?](https://longbridge.com/en/news/292854144.md)